title: [Hemostasis-altering drugs and regional anesthetic techniques: safety guidelines].
abstract: New developments--in the form of emerging clinical settings for regional anesthesia as well as problems arising with the concomitant use of regional techniques and hemostasis-altering drugs--require the ongoing revision of safety guidelines. The annual meeting of ESRA held in Spain in 2003 saw the discussion and clarification of a variety of issues of current concern, including conclusions reached on the estimated risk of spinal hematoma when published safety guidelines are followed or not, precautions to take in epidural anesthesia during cardiac surgery, guidelines for using fondaparinux for thromboprophylaxis, the circumstances under which neuroaxial techniques can be used safely in patients under the effects of platelet aggregation inhibitors such as thienopyridine, and the application of epidural anesthesia in parturients with eclampsia who have received platelet aggregation inhibitors. Conclusions drawn at the meeting enrich and clarify certain important safety issues related to local and regional anesthesia in patients receiving antiplatelet drugs and/or anticoagulants.
authors.affiliation: Servicio de Anestesiología, Hospital Clínico Universitario, Valencia.
authors.forename: J V
authors.initials: JV
authors.lastname: Llau Pitarch
authors.forename: J
authors.initials: J
authors.lastname: De Andrés Ibáñez
authors.forename: C
authors.initials: C
authors.lastname: Gomar Sancho
authors.forename: A
authors.initials: A
authors.lastname: Gómez Luque
authors.forename: F
authors.initials: F
authors.lastname: Hidalgo Martínez
authors.forename: L M
authors.initials: LM
authors.lastname: Torres Morera
mesh_terms: D000765:Anesthesia, Conduction / Q000379:methods*; D000767:Anesthesia, Epidural / Q000379:methods; D000773:Anesthesia, Obstetrical / Q000379:methods; D000775:Anesthesia, Spinal / Q000379:methods; D000777:Anesthetics / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology; D000075202:Contraindications; D005112:Extracorporeal Circulation; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000494:pharmacology; D000077425:Fondaparinux; D006406:Hematoma / Q000209:etiology / Q000517:prevention & control; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D011134:Polysaccharides / Q000009:adverse effects; D011183:Postoperative Complications / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D012307:Risk Factors; D012449:Safety; D013122:Spinal Diseases / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D000777:Anesthetics; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D011134:Polysaccharides; D000077425:Fondaparinux